Literature in Oncology: Prostate Cancer
De Bari B, Alongi F, Lestrade L, Giammarile F.
Choline-PET in prostate cancer management: The point of view of the radiation oncologist.
Crit Rev Oncol Hematol. 2014 Sep;91(3):234-247.
Chondrogiannis S, Marzola MC, Ferretti A, Grassetto G, Maffione AM, Rampin L, Fanti S, Giammarile F, Rubello D.
Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1293-300.
Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, Nanni C, Colletti PM, Rubello D.
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1356-64.
Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM.
The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.
Eur Urol. 2013 Jul;64(1):106-17.
Jadvar H.
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S5-10.
Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I.
18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.
Prostate Cancer Prostatic Dis. 2012 Mar;15(1):45-55.
Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, Maccagnano C, Liguori G, Valentino M, Battaglia M, Barozzi L.
Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).
World J Urol. 2011 Oct;29(5):595-605.
Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K, Pascal O, Cussenot O, Talbot JN.
Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
Q J Nucl Med Mol Imaging. 2011 Aug;55(4):448-57.
Jadvar H.
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
J Nucl Med. 2011 Jan;52(1):81-9.
Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O, Senthamizhchelvan S, Zaidi H.
18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer.
Radiother Oncol. 2009 Nov;93(2):220-5.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I.
The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
J Nucl Med. 2006 Feb;47(2):287-97.
Langsteger W, Heinisch M, Fogelman I.
The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
Semin Nucl Med. 2006 Jan;36(1):73-92.
Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H.
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
J Nucl Med. 2004 Mar;45(3):366-73.